News | April 12, 2024
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Total value of the supplies of FC will be US$ 2.773 million
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Fluid bed processes: drying, granulating, and coating in just one product container
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
This acquisition enables MTD to open new, strategic markets
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Executes the first project for developing and manufacturing a novel anticancer mAb
Subscribe To Our Newsletter & Stay Updated
